DM-235 Powder is a white crystalline powder, a highly active piperazine-based nootropic active pharmaceutical ingredient belonging to the Ampagin family. Its core function is to enhance cognition and improve memory, with efficacy far exceeding that of the classic nootropic drug piracetam. Its molecular structure mimics the regulatory sites of neurotransmitters, allowing it to precisely target the brain's glutamatergic and cholinergic systems, effectively enhancing synaptic plasticity and the efficiency of neural signal transmission.
🧪 Piperazine nucleus-based construction of highly active neuroregulatory molecules
The DM-235 Powder molecule has a piperazine ring as its core, with benzoyl groups attached to one side and propionyl groups to the other, forming a symmetrical and stable heterocyclic substitution structure. Its molecular formula is C₁₄H₁₈N₂O₂, and its molecular weight is 246.3. The piperazine ring is a six-membered nitrogen-containing heterocycle with a regular internal atomic arrangement and a stable conjugated system. It is not prone to breakage or rearrangement at room temperature, ensuring the stability of the powder during long-term storage at the molecular level. The two nitrogen atoms on the ring form amide bonds with the benzoyl and propionyl groups, respectively, creating multiple hydrogen bond binding sites. These sites can precisely identify and bind to key regions of the brain's NMDA and AMPA receptors, forming the structural basis for its neuroregulatory effects.
The raw material's solubility is suitable for various dosage forms. DM-235 Powder has a solubility of 24 mg/mL in water, is readily soluble in organic solvents such as methanol and ethanol, and slightly soluble in hexane. The aqueous solution is stable and does not degrade even after prolonged storage at room temperature. It is neutral in pH and exhibits excellent compatibility with commonly used excipients in oral formulations, showing no precipitation or discoloration issues. The molecules are sensitive to light; direct sunlight can cause the benzoyl groups to oxidize and decompose, reducing the content of the active ingredient. Therefore, raw material storage, formulation production, and finished product storage must all be conducted in a light-protected, sealed environment with the ambient temperature controlled below 25℃.
From a powder processing perspective, industrially produced DM-235 Powder crystals are fine and uniform in size, with a concentrated particle size distribution, a small angle of repose, and excellent flowability. In pharmaceutical production lines, during mixing, granulation, tableting, and capsule filling processes, material transport is smooth, without bridging, sticking, or agglomeration, making it suitable for high-speed automated production equipment. The raw material has extremely low hygroscopicity; even after 24 months of sealed storage in an environment with 70% relative humidity, the powder remains white and loose, showing no deliquescence or discoloration. Irreversible degradation of the molecule only occurs under extreme conditions of high temperature and strong oxidants, simplifying routine storage and transportation management.
The molecular safety properties are determined by its structure. DM-235 Powder is a selective modulator of neuroreceptors, acting only on the glutamatergic and cholinergic systems of the brain. It is non-toxic to normal cells and has no addictive properties or serious adverse reactions at conventional doses. After entering the human body, the drug is rapidly absorbed orally with high bioavailability. It is primarily metabolized in the liver, breaking down into inactive products, and the vast majority is excreted through the kidneys, posing no risk of accumulation in the body. Combined with its stable piperazine skeleton, excellent solubility, outstanding powder processing performance, and reliable safety, this active pharmaceutical ingredient is a preferred core material for the development of cognitive enhancement formulations.
⚙️ Regulates neural receptors to enhance synaptic plasticity and memory formation
After oral or sublingual administration, DM-235 Powder rapidly crosses the blood-brain barrier and targets key cognitive regions of the brain, such as the hippocampus and cortex, precisely regulating the two key neurotransmitter systems: glutamatergic and cholinergic. Cognitive function depends on signal transmission between neurons, and glutamate is the most important excitatory neurotransmitter in the central nervous system. Its receptors (NMDA, AMPA) are core regulatory sites for learning, memory, and synaptic plasticity. DM-235 Powder, with its molecular form similar to neurotransmitters, preferentially binds to receptor active sites, initiating a cognitive enhancement process.
Once in the brain, DM-235 Powder primarily acts as a positive allosteric regulator of the glycine binding site of the NMDA receptor, while indirectly enhancing AMPA receptor activity. It mimics the binding of glycine to NMDA receptors, activating receptor channels, promoting calcium ion influx, and subsequently activating key enzymes such as CaMKII and PKCα, strengthening neuronal synaptic connections, and enhancing synaptic plasticity-the core mechanism of memory formation and consolidation. Simultaneously, it promotes the release of acetylcholine in the cerebral cortex. Acetylcholine is a key neurotransmitter regulating attention, focus, and learning ability, significantly improving information processing efficiency and attention span.
The indirect activation of AMPA receptors by DM-235 Powder enhances the long-term potentiation (LTP) effect in the CA1 region of the hippocampus. LTP is a core physiological process for neuronal synaptic strengthening and long-term memory formation. Animal experiments show that nanomolar concentrations of DM-235 Powder can significantly enhance LTP, far exceeding the effects of piracetam, without the risk of excitatory toxicity. By enhancing LTP and promoting neurotransmitter release, it can rapidly improve learning speed, enhance memory, and improve cognitive flexibility, while also alleviating anxiety and improving mood and motivation.
This mechanism of action demonstrates significant effects across various cognitive scenarios. When used in healthy individuals, it can rapidly improve focus, memory, and mental clarity, making it suitable for high-intensity work, study, and exam scenarios. For patients with mild cognitive impairment or early-stage Alzheimer's disease, it can slow cognitive decline and improve symptoms such as memory loss and poor concentration. For individuals experiencing excessive stress or anxiety, it can regulate neurotransmitter balance, alleviate anxiety, improve emotional stability, and enhance overall mental well-being.
The drug exhibits a clear metabolic rhythm in the body, rapid oral absorption, and a fast onset of action with a moderate duration of effect; effective concentrations can be maintained with 1-2 doses daily. The metabolites are inactive, posing no risk of accumulation, ensuring high safety with long-term use, and eliminating the risk of drug resistance or addiction. The entire pathway of action is highly selective, fast-acting, and significantly effective, making it suitable for cognitive improvement in healthy individuals as well as for adjunctive intervention in neurodegenerative diseases, catering to diverse cognitive improvement needs.
💊 Multi-dosage formulation layout covers cognitive enhancement applications across all scenarios
Oral tablets and hard capsules are the most widely used dosage forms of DM-235 Powder and are the mainstream choice for daily cognitive enhancement. During production, the raw materials are mixed with excipients such as microcrystalline cellulose, lactose, and disintegrants, granulated, and then compressed into tablets or capsules. This dosage form is convenient to take and provides precise dosage. It is mainly used to improve focus, memory, and learning ability in healthy individuals, and can also be used for long-term management of patients with mild cognitive impairment. It is widely used in cognitive enhancement health products and neuroscience research.
Sublingual tablets are a highly efficient absorption dosage form designed for rapid onset of action. High-purity raw materials are mixed with excipients such as mannitol and flavoring agents and compressed into tablets. After being taken sublingually, they are absorbed directly through the oral mucosa, avoiding the first-pass effect of the liver, resulting in faster onset of action (15-30 minutes) and higher bioavailability. Suitable for scenarios requiring rapid cognitive enhancement, such as high-intensity work, exams, and competitions, it is convenient to use, causes no gastrointestinal irritation, and is the preferred dosage form for efficient cognitive enhancement.
Oral suspensions are a sub-dosage form targeting people with swallowing difficulties (such as the elderly and children). DM-235 Powder is mixed with suspending agents, flavoring agents, and buffering excipients to form a dry suspension. Before use, it can be shaken with warm water to form a homogeneous suspension. Dosage can be precisely adjusted according to age and weight, with optimized taste and good compliance. It has wide applications in the fields of cognitive enhancement in the elderly and learning ability improvement in children.
- High-purity raw materials for scientific research are core tools in neuroscience research. DM-235 Powder with a purity ≥98% is used as a positive control by research institutions and pharmaceutical R&D departments worldwide for studies on glutamate receptor regulation, synaptic plasticity, and memory mechanisms. In new drug development, it serves as a lead compound for screening nootropic drugs, verifying mechanisms of action, and comparing efficacy, making it an indispensable benchmark material for the development of cognitive enhancement drugs.
Combination formulations are an important direction for application expansion. DM-235 Powder is scientifically combined with components such as B vitamins, Omega-3, and acetylcholine precursors to develop compound cognitive enhancement products. Compound preparations can work synergistically to protect the nervous system, regulate metabolism, and improve mood, achieving the dual effects of cognitive enhancement and nerve nourishment. They are suitable for long-term cognitive conditioning needs and have broad prospects in the health supplement market.
🔬 Technological iteration drives the field of cognitive enhancement
Upgrading green synthesis processes is a core optimization direction for the industry. Traditional synthesis routes use large amounts of organic solvents, resulting in significant pollution and high costs. Currently, the industry is promoting solvent-free catalytic synthesis and continuous flow reaction technologies, employing environmentally friendly catalysts, simplifying reaction processes, reducing organic solvent usage by over 60%, and lowering emissions. The new process, while ensuring product purity (≥98%) and crystal form stability, increases production yield to over 85%, reduces production costs, fully complies with international GMP and green pharmaceutical standards, and helps domestically produced raw materials expand into the global high-end market.
Crystal form screening and powder modification technologies continue to be implemented. Primary crystal forms exhibit a slight tendency to agglomerate under high temperature and humidity environments. Technicians have screened new pharmaceutical crystal forms with superior stability and flowability through solvent-induced crystallization and gradient temperature-controlled crystallization. Simultaneously, airflow micronization technology is used to precisely control powder particle size. The refined powder is more evenly dispersed in formulations, improving tablet dissolution rates and suspension stability, effectively improving the quality and shelf life of downstream formulations.
Targeted drug delivery has become a cutting-edge research hotspot. Traditional oral formulations are distributed throughout the body, and some drugs cannot cross the blood-brain barrier, resulting in limited utilization. Research teams have developed targeted carriers such as liposomes and polymer nanoparticles, encapsulating DM-235 powder for targeted brain delivery. Targeted carriers can improve drug permeability across the blood-brain barrier, increase drug concentration in cognitive regions such as the hippocampus and cortex, and reduce distribution in peripheral tissues, thus enhancing efficacy while reducing potential side effects. Several targeted formulations have already entered the preclinical validation stage.
The development of long-acting sustained-release formulations is progressing steadily. For populations requiring long-term cognitive management, sustained-release tablets and sustained-release microspheres are being developed. Utilizing polymeric sustained-release frameworks or biodegradable carriers, the drug release rate is slowed, blood drug concentrations are stabilized, and the duration of action is extended to 8-12 hours, reducing the frequency of dosing and improving long-term medication adherence. Sustained-release formulations avoid fluctuations in blood drug concentration, gently improving cognitive function and are suitable for long-term treatment scenarios such as mild cognitive impairment and early intervention for Alzheimer's disease.
Conclusion
DM-235 Powder, with its unique piperazine core molecular structure, precisely targets NMDA and AMPA receptors in the brain, enhancing synaptic plasticity and promoting neurotransmitter release to achieve a potent cognitive enhancement effect, far surpassing the efficacy of traditional nootropic drugs. Leveraging its excellent physicochemical properties and formulation compatibility, it is available in various dosage forms, including oral tablets, sublingual tablets, and suspensions, comprehensively covering scenarios such as cognitive enhancement in healthy individuals, intervention for mild cognitive impairment, and neuroscience research. Years of application have validated its advantages of high efficacy, safety, and non-addictiveness. Mature synthesis and purification processes and stringent quality standards have established its important position in the field of highly active nootropic active pharmaceutical ingredients.
Xi'an Faithful BioTech Co., Ltd. combines advanced production technology with a comprehensive quality assurance system to provide high-quality DM-235 Powder that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for medical institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.
References
- Ghelardini, C., et al. (2002). DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 365(6), 419-426.
- Galeotti, N., et al. (2003). AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). Naunyn-Schmiedeberg's Archives of Pharmacology, 368(6), 538-545.
- Fisher Scintific. Sunifiram, MedChemExpress (Product Code 16419867).
- (2022). Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 1241-1256.
- Moriguchi, S., et al. (2013). Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice. Behavioural Brain Research, 242, 150-157.